Jade Biosciences (JBIO) News Today

Jade Biosciences, Inc. (NASDAQ:JBIO) shares are reacting to a flurry of analyst actions this morning, with new buy ratings and earnings upgrades from Wedbush offset by a handful of downward revisions and a reiterated sell rating.

• Positive Sentiment: BTIG initiates coverage of JBIO with a Buy recommendation.BTIG Initiates Coverage with Buy
• Positive Sentiment: BTIG Research sets a $28.00 price target (208% upside) on JBIO.JBIO Initiated with Bullish View at BTIG
• Positive Sentiment: Analysts award JBIO an average “Moderate Buy” rating from five firms.Moderate Buy from Analysts
• Positive Sentiment: Wedbush lifts Q4 2026 EPS estimate to ($0.46) from ($0.57) and retains an “Outperform” rating with an $18 target.Wedbush Free Report
• Positive Sentiment: Wedbush boosts Q3 2026 EPS forecast to ($0.44) from ($0.52).Wedbush Free Report
• Positive Sentiment: Wedbush ups Q2 2026 EPS to ($0.53) from ($0.64).Wedbush Free Report
• Positive Sentiment: Wedbush raises Q1 2026 EPS to ($0.51) from ($0.57).Wedbush Free Report
• Positive Sentiment: Wedbush lifts FY 2026 EPS to ($1.92) from ($2.28).Wedbush Free Report
• Neutral Sentiment: Reported spike in October short interest (though levels remain at zero shares, making data inconclusive).
• Negative Sentiment: Wedbush lowers Q4 2025 EPS estimate to ($0.58) from ($0.49).Wedbush Free Report
• Negative Sentiment: Wedbush drops Q3 2025 EPS forecast to ($0.72) from ($0.43).Wedbush Free Report
• Negative Sentiment: Wedbush cuts FY 2025 EPS to ($4.62) from ($4.35).Wedbush Free Report
• Negative Sentiment: Weiss Ratings reiterates a Sell (E-) rating on JBIO.Sell (E-) from Weiss Ratings

Overall, fresh buy initiations from BTIG and multiple upward earnings revisions by Wedbush are underpinning positive sentiment, while some near-term EPS downgrades and a reiterated sell rating from Weiss introduce caution into JBIO’s trading dynamics.